APR 1.1 2008

Attorney Docket Number

0.0111.455150

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Demark Office; U.S. DEPARTMENT OF COMMERCE
n unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

1

Sheet

Application Number 10/519,838

Filing Date December 08, 2005

First Named Inventor Eduardo N. MITRANI et al

Art Unit 1651

Examiner Name KIM, TAEYOON

28888

			U.S. PATENT	DOCUMENTS	_
Examiner Initials*	Cite No. 1	Document Number	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)}			- · · ·
	1	US-1,516,071	18-Nov-2024	Apolant	
	2	US-2002/0068880	06-Jun-2002	Burbank et al.	
	3	US-3,076,461	05-Feb-1963	Meek et al.	
	4	US-3,613,242	19-Oct-1971	Hill et al.	
	5	US-4,115,346	19-Sep-1978	Gross et al.	
	6	US-4,973,301	27-Jan-1990	Nissenkorn	
	7	US-5,333,951	02-Aug-1994	Wakoh	
	8	US-5,376,123	27-Dec-1994	Klaue et al.	
	9	US-5,491,692	13-Feb-1996	Gunner et al.	
	10	US-5,516,680	14-May-1996	Naughton et al.	
	11	US-5,518,498	21-May-1996	Lindenberg et al.	
	12	US-5,578,035	26-Nov-1996	Lin	
-	13	US-5,759,830	02-Jun-1998	Vacanti et al.	
	14	US-5,958,764	28-Sep-1999	Roop et al.	
	15	US-5,980,887	09-Nov-1999	Isner et al.	
	16	US-6,036,657	14-Mar-2000	Milliman et al	
	17	US-6,197,575	06-Mar-2001	Griffith et al.	
	18	US-6,264,659	24-Jul-2001	Ross et al.	
			FOREIGN PATE	ENT DOCUMENTS	

3

Examiner Cite			Dublication Date	Name of Detentes on	Pages, Columns, Lines,	Г
Initials*	No. 1	Foreign Patent Documents	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T 6
	ļ	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	DD 11111111111111111111111111111111111			L
	19	EP 0895380	12-Mar-1998	Asprey		L
	20	JP 2000-125863	09-May-2000	Ueda et al.		
	21	GB 408668	12-Apr-1934	Norman et al.		
	22	DE 4104092	14-Aug-1991	Rieger		Γ
	23	PCT WO 00/09668	24-Feb-2000	Snyder et al.		
	24	PCT WO 98/16158	23-Apr-1998	Ysebaert		П
	25	PCT WO 99/39661	12-Aug-1999	Wolinsky et al.		
	<u> </u>					ـ
	 					\vdash
Examiner				Date		
Signature				Considered		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

Appricant is to place a check mark increase translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/519,838 Filing Date December 08, 2005 SUPPLEMENTAL First Named Inventor Eduardo N. MITRANI et al INFORMATION DISCLOSURE STATEMENT BY APPLICANT Group Art Unit 1651 (use as many sheets as necessary) Examiner Name KIM, TAEYOON Attorney Docket Number 28888 Sheet Of OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), No.1 T^2 Initials publisher, city and/or country where published. Bergold et al. "Transsynaptic Neuronal Loss Induced in Hippocampal Slice 26 Cultures by A Herpes Simplex Virus Vector Expressing the GluR6 Subunit of the Kainate Receptor", Proc. Natl. Acad. Sci. USA, 90: 6165-6169, 1993. Bradl et al. "Malignant Melanoma in Transgenic Mice", Proc. Natl. Acad. Sci. 27 USA, 88: 164-168, 1991. Choate et al. "Direct Cutaneous Gene Delivery in A Human Genetic Skin Disease", 28 Human Gene Therapy, 8: 1659-1665, 1997. 29 Clark et al. "Islet Cell Culture in Definded Serum-Free Medium", Endocrinology, 126(4): 1895-1903, 1990. 30 Furth et al. "Gene Transfer by Jet Injection Into Differentiated Tissues of Living Animals and in Organ Culture", Molecular Biotechnology, 4: 121-127, 1995. 31 Game et al. "Rejection Mechanisms in Transplantation", Wiener Klinische Wochenschrift, 113(20-21): 832-838, 2001. German et al. "Regulation of Insulin Gene Expression by Glucose and Calcium in 32 Transfected Primary Islet Cultures", The Journal of biological Chemistry, 265(36): 22063-22066, 1990. Hortelano et al. "Delivery of Human Factor IX in Mice by Encapsulated 33 Recombinant Myoblasts: A Novel Approach Towards Allogeneic Gene Therapy of Hemophilia B", Blood, 87(12): 5095-5103, 1996. 34 lizuka et al. "Effects of Retinoids on the Cyclic AMP System of Pig Skin Epidermis", The Journal of Investigative Dermatology, 85(4): 324-327, 1985. Laub et al. "Expression of the Human Insulin Gene and cDNA in A Heterologous 35 Mammalian System", The Journal of Biological Chemistry, 258(10): 6043-6050, Lippin et al. "Human Erythropoietin Gene Therapy for Patients With Chronic Renal 36 Failure", Blood, 106(7): 2280-2286, 2005. 37 Metrakos et al. "Intercellular Communication and Maintenance of Islet Cell Mass -Implications for Islet Transplantation", Surgery, 114: 423-428, 1993. 38 Mintz et al. "Transgenic Mouse Model of Malignant Skin Melanoma", Proc. Natl. Acad, Sci. USA, 90: 8817-8821, 1993. Mole et al. "Structure and Function of SV40 Large-T Antigen", Philosophical 39 Transactions of the Royal Society of London, Series B, Biological Sciences, 317(1187): 455-469, 1987.

Date

Considered

Examiner

Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/519,838 Filing Date December 08, 2005 **SUPPLEMENTAL** INFORMATION DISCLOSURE First Named Inventor Eduardo N. MITRANI et al Art Unit 1651 STATEMENT BY APPLICANT **Examiner Name** KIM, TAEYOON (use as many sheets as necessary) Attorney Docket Number 28888 3 Sheet 3 Of OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite Initials4 No. item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. T^2 40 Montaña et al. "Beta Cell Mass and Growth After Syngeneic Islet Cell Transplantation in Normal and Streptozocin Diabetic C57BL/6 Mice", Journal of Clinical Investigation, 91: 780-787, 1993. Paus et al. "Correlation of Proteolytic Activities of Organ Cultured Intact Mouse 41 Skin With Defined Hair Cycle Stages", Journal of Dermatological Science, 7: 202-209, 1994. 42 Platt "Knocking Out Xenograft Rejection", Nature Biotechnology, 20: 231-232, 43 Sharkawy et al. "Engineering the Tissue Which Encapsulates Subcutaneous Implants. I. Diffusion Properties", Journal of Biomedicine & Material Research, 37: 401-412, 1997. 44 Thompson et al. "Expression of Transforming Growth Factor-Beta1 in Specific Cells and Tissues of Adult and Neonatal Mice", The Journal of Cell Biology, 108: Wang et al. "Transgenic Studies With Keratin Promoter-Driven Growth Hormone 45 Transgene: Prospects for Gene Therapy", Proc. Natl. Acad. Sci. USA, 94: 219-226, 1997. Yu et al. "Importance of FSH-Releasing Protein and Inhibin in 46 Erythrodifferentiation", Nature, 330: 765-767, 1987. Abstract.

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450